PMDA — authorised 21 September 2018
- Marketing authorisation holder: Pfizer Japan Inc.
- Status: approved
PMDA authorised Fusilev on 21 September 2018
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 21 September 2018.
Pfizer Japan Inc. holds the Japanese marketing authorisation.